Connect with us

Published

on

Charles Liang, CEO, Super Micro 

Source: Supermicro 

It’s been a brutal year for tech stocks. The Nasdaq is headed for its worst slump since 2008 and is poised to underperform the S&P 500 for a second straight year. Among mega-cap tech stocks, Amazon, Meta and Tesla have each lost at least half their value.

Investors looking for some sign of optimism can turn to a 29-year-old server maker located in the heart of Silicon Valley. Shares of Super Micro Computer have soared 89% in 2022, topping all other U.S. tech companies valued at $1 billion or more. Supermicro has a market cap of $4.4 billion, up from $2.4 billion at the start of the year.

related investing news

These 'recession-resistant' cybersecurity stocks have over 60% upside, analysts say

CNBC Pro
Will 2023 be a better year for the chip sector? Wall Street pros weigh in and share their top picks

CNBC Pro

Supermicro manufactures computers and sells them to companies, which use them as servers for websites, data storage and applications like artificial intelligence algorithms. In the low-margin server business, Supermicro competes with Dell, IBM and Hewlett Packard Enterprise as well as lesser-known players such as China’s Inspur. According to estimates from The Next Platform, Supermicro had about 2.6% of the market in 2021.

Supermicro has sought to differentiate itself in the market by allowing customers to more easily customize their computers. That makes for a more profitable offering than off-the-shelf servers.

The strategy has been working. Supermicro reported 46% growth in its fiscal 2022, which ended in June, to $5.2 billion in revenue. Earnings per share climbed to $5.32 in 2022 from $2.09 in 2021 and $1.60 the year before that.

“The stock is actually just simply mirroring the EPS increases we have seen over two years,” said Nehal Chokshi, an analyst at Northland Capital Markets who recommends buying the stock. Chokshi has a price target of $165, by far the highest among five analysts tracked by FactSet.

Supermicro closed on Tuesday at $82.89.

Chokshi said that Supermicro’s profitability and growth have been strong enough that it might deserve a larger multiple. Yet even with this year’s rally, the stock is only trading at 8.6 times earnings over the next 12 months, which is lower than its five-year average of 9.5, according to FactSet. For the past 12 months, it trades at 10.1 times earnings, down from a five-year average of 17.8.

“There still hasn’t been multiple expansion,” Chokshi said. “A lot of investors, including myself, find that befuddling, because this is a name that has historically generated 20-plus percent revenue and EPS growth that’s trading only at 10 [times] earnings.”

Jim Cramer gives his take on Super Micro Computer

Across the board, investors have taken a hatchet to tech multiples, reflecting concerns that soaring inflation and rising interest rates will dampen enthusiasm for growth stocks for the foreseeable future. The Nasdaq currently trades for 26 times earnings, compared with its five-year average of 35, according to FactSet.

Supermicro shares started rising in July and continued going up in August, after the company’s annual earnings report. They soared another 30% in November, after Supermicro showed a nearly 80% increase in year-over-year sales for the September quarter to $1.85 billion.

Manufacturing servers involves putting many different parts together. Supermicro starts with one of its own motherboards, plugs in a processor from Intel or AMD, or a graphics processor from Nvidia, and adds a power supply, RAM, networking and whatever other parts the computer might need. Supermicro will sell the client the motherboard, a fully assembled server, or an entire rack of servers.

Heading into 2023, the outlook for the server market is murky, especially in the early part of the year. Companies are tightening their belts, and likely to spend less on capital expenditures. Supermicro’s revenue growth is expected to moderate to about 32% in fiscal 2023 and 9% the following year.

But the company has at least regained the support of Wall Street after a rough stretch in the middle of the last decade. From 2015 through 2017, Supermicro had misstated financial statements and published some key filings late, according to the SEC.

Super Micro plunges on new report of hacked hardware in US

“They have done a marvelous job of coming back,” said Susquehanna’s Mehdi Hosseini, who has a hold rating on the stock. “I would say they’re the comeback story of 2022. And that’s what’s reflected in the share price. But the management team has to remain very aggressive with their target.”

The comeback, according to Hosseini, is partially driven by confidence in CFO David Weigand, who has implemented strong internal financial controls since taking the job in early 2021.

“They became compliant with SEC filings in 2020, and it’s just been straight line up,” Hosseini said. “They have done really well.”

Bigger customers

Supermicro CEO Charles Liang told CNBC that the company’s recent performance reflects the size of the business and its ability to offer a wider array of products, particularly around customization.

While the company has been rapidly expanding in Taiwan, one component of its differentiation strategy, Liang said, is its San Jose, California, headquarters, where Supermicro still does the majority of its manufacturing.

Liang said it’s more expensive to build locally than overseas but doing so allows the company to be physically closer and more responsive to the chip companies it supplies as well as major customers like cloud providers and big websites.

“Silicon Valley enables us for better technology, faster time to market, and quick service, quick maintenance of our customer,” Liang said.

He said tech companies can move faster with Supermicro servers and are willing to pay for execution and the company’s design skills.

One area of notable growth is machine learning, or AI algorithms that require a large amount of computing power, usually centered around graphics processors made by Nvidia or AMD. Supermicro makes motherboards and systems that can combine up to eight GPUs together on a single board.

In the latest quarter, 45% of Supermicro’s revenue came from enterprise sales, including AI and machine learning products.

Another specialized market Supermicro is targeting is servers for 5G or telecom applications, using a new kind of approach called OpenRAN.

Supermicro is targeting $8 billion to $10 billion in revenue for fiscal 2024. To reach that goal, the company says it needs substantial growth from AI products and has to sell more complete systems, or servers already installed in a rack.

Current growth is being driven by Supermicro’s large data center business, which has been landing bigger accounts and comprised 50% of total sales in the September quarter, according to a November note from Wedbush analyst Matt Bryson, who has a neutral rating on the stock.

Supermicro said in November that a big unnamed customer was responsible for nearly 22% of the company’s sales in the quarter. In recent years, Supermicro had no single customer accounting for more than 10% of its sales.

‘Far more cautious’

Among analysts, there’s some skepticism that the company can hit its targets in a softer economic environment.

Susquehanna’s Hosseini said he recently downgraded the stock “because I think they will face headwinds in the next year” and the “growth targets are too aggressive.”

Intel and AMD have issued downbeat prospects for the server market, and companies of all sizes are cutting costs.

“While we applaud the quarter, we are far more cautious when thinking about Supermicro’s intermediate to longer term path and in particular view the company’s now stated goal of $8 billion to $10 billion in revenues in 2024 with trepidation given the headwinds noted above,” Wedbush’s Bryson wrote.

Analysts at Evercore said in a note this month that they expect server market revenue growth to slow to about 2.7% globally in 2023 from 13.5% last year. Server makers like Supermicro need to carry a lot of inventory and may face margin pressure if sales slow.

Northland’s Chokshi said that Supermicro’s strengths, especially in AI systems, could allow it to weather a market downturn better than its rivals.

“While their competitors are showing strong signs that there is a significant capex down cycle, their results are accelerating,” Chokshi said. “So far, they’re showing no signs of this cycle catching up to them.”

Liang is confident that Supermicro can continue to gain new customers, even if growth slows from its recent torrid pace.

“In a good year, growth will be around 80%,” he said. “In a bad year, hopefully 20%.”

WATCH: Tech stock expectations are coming down but not fast enough

Tech stock expectations are coming down but not fast enough, says MKM Partners' Rohit Kulkarni

Continue Reading

Technology

Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million

Published

on

By

Anne Wojcicki has a new offer to take 23andMe private, this time for .7 million

Anne Wojcicki attends the WSJ Magazine Style & Tech Dinner in Atherton, California, on March 15, 2023.

Kelly Sullivan | Getty Images Entertainment | Getty Images

23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities and Exchange Commission.

Wojcicki and New Mountain have offered to acquire all of 23andMe’s outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million. The company’s stock closed at $2.42 on Friday with a market cap of about $65 million.

The offer comes after a turbulent year for 23andMe, with the stock losing more than 80% of its value in 2024. In January, the company announced plans to explore strategic alternatives, which could include a sale of the company or its assets, a restructuring or a business combination. 

Read more CNBC tech news

23andMe has a special committee of independent directors in place to evaluate potential paths forward. The company appointed three new independent directors to its board in October after all seven of its previous directors abruptly resigned the prior month. The special committee has to approve Wojcicki and New Mountain’s proposal.

“We believe that our Proposal provides compelling value and immediate liquidity to the Company’s public stockholders,” Wojcicki and Matthew Holt, managing director and president of private equity at New Mountain, wrote in a letter to the special committee on Thursday.

Wojcicki previously submitted a proposal to take the company private for 40 cents per share in July, but it was rejected by the special committee, in part because the members said it lacked committed financing and did not provide a premium to the closing price at the time.

Wojcicki and New Mountain are willing to provide secured debt financing to fund 23andMe’s operations through the transaction’s closing, the filing said. New Mountain is based in New York and has $55 billion of assets under management, according to its website.

23andMe declined to comment.

WATCH: The rise and fall of 23andMe

The rise and fall of 23andMe

Continue Reading

Technology

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Published

on

By

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Hims & Hers

Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.

Semaglutide is the active ingredient in Novo Nordisk‘s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been prescribing compounded semaglutide as an alternative for patients who are navigating volatile supply hurdles and insurance obstacles.

Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA doesn’t review the safety and efficacy of compounded products.

Hims & Hers began offering compounded semaglutide to patients in May, and it owns compounding pharmacies that produce the medications.

Compounded medications are typically much cheaper than their branded counterparts. Hims & Hers sells compounded semaglutide for less than $200 per month, while Ozempic and Wegovy both cost around $1,000 per month without insurance.

Read more CNBC tech news

The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days, depending on the type of facility, in order to “avoid unnecessary disruption to patient treatment.”

“Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO Andrew Dudum posted Friday on X. “We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have ‘capacity limitations’ and ‘expected continued periodic supply constraints and related drug shortage notifications.'”

Him & Hers’ weight loss offerings have been a massive hit with investors. Shares of the company climbed more than 200% last year, and the stock is already up more than 100% this year despite Friday’s move.

Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.

Despite the turbulent regulatory landscape, Hims & Hers has showed no signs of slowing down.

On Friday, the company announced it has acquired a U.S.-based peptide facility that will “further verticalize the company’s long-term ability to deliver personalized medications.” Hims & Hers will explore advances across metabolic optimization, recovery science, biological resistances, cognitive performance and preventative health through the acquisition, the company said.

That move comes just days after Hims & Hers also bought Trybe Labs, the New Jersey-based at-home lab testing facility. Trybe Labs will allow Hims & Hers to perform at-home blood draws and more comprehensive pretreatment testing.

Hims & Hers did not disclose the terms of either deal.

WATCH: Hims & Hers Super Bowl ad sparks controversy

Hims & Hers Super Bowl ad sparks controversy

Continue Reading

Technology

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Published

on

By

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Tesla models Y and 3 are displayed at a Tesla dealership in Corte Madera, California, on Dec. 20, 2024.

Justin Sullivan | Getty Images

Tesla is voluntarily recalling 376,241vehicles in the U.S. to correct an issue with failing power-assisted steering systems, according to records posted to the website of the U.S. National Highway Traffic Safety Administration.

In a safety recall report posted on the NHTSA website, Tesla said the recall includes Model 3 and Model Y vehicles that were manufactured for sale in the U.S. from Feb. 28, 2023, to October 11, 2023, and that were equipped with a certain older software release.

The records said printed circuit boards in the steering systems in affected vehicles could become overstressed, causing the power-assist steering to fail in some cases when a Tesla vehicle rolled to a stop and then accelerated.

When electronic power-assist steering systems fail in a Tesla, drivers need to exert more force to steer their cars, which can increase the risk of a collision.

Read more CNBC tech news

Tesla told the vehicle safety regulator that it was not aware of any crashes, injuries or deaths related to the power steering failures, and that it was offering an over-the-air software update as a remedy.

The recall follows an earlier related probe and voluntary recall in China concerning the same systems.

President Donald Trump has appointed Tesla CEO Elon Musk to lead a team that is slashing the federal government workforce, and in some cases, regulations and entire agencies. Those cuts already affected the NHTSA, an agency Musk has long seen as standing in the way of some of his ambitions at Tesla.

The regulator has been engaged in a yearslong investigation into safety defects in the systems that Tesla markets currently as its Autopilot and Full Self-Driving (Supervised) options. The features do not make Tesla cars into robotaxis. They require a human driver ready to steer or brake at any time.

The Washington Post reported on Thursday that Musk’s team has led mass firings at the NHTSA, reducing the agency’s workforce and capacity to investigate companies including Tesla by about 10%.

Tesla didn’t respond to a request for comment.

WATCH: Tesla stock hinges on new vehicles being introduced

Tesla stock hinges on new vehicles being introduced, says Canaccord's  George Gianarikas

Continue Reading

Trending